Carsten Brunn - 13 Nov 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
President and CEO, Director
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Carsten Brunn
Issuer symbol
RNAC
Transactions as of
13 Nov 2023
Net transactions value
-$2,383,268
Form type
4
Filing time
15 Nov 2023, 17:26:14 UTC
Previous filing
26 Sep 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SELB Common Stock Disposed to Issuer $113,300 -55,000 -7% $2.06 728,081 13 Nov 2023 Direct F1
transaction SELB Common Stock Disposed to Issuer $28,016 -13,600 -1.9% $2.06 714,481 13 Nov 2023 Direct F2
transaction SELB Common Stock Disposed to Issuer $349,634 -169,725 -24% $2.06 544,756 13 Nov 2023 Direct F3
transaction SELB Common Stock Disposed to Issuer $582,568 -282,800 -52% $2.06 261,956 13 Nov 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -1,000,000 -100% 0 13 Nov 2023 Common Stock 1,000,000 $6.03 Direct F5
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -330,000 -100% 0 13 Nov 2023 Common Stock 330,000 $2.20 Direct F6
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer $124,000 -400,000 -100% $0.3100 0 13 Nov 2023 Common Stock 400,000 $1.75 Direct F7
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -600,000 -100% 0 13 Nov 2023 Common Stock 600,000 $2.30 Direct F8
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -75,000 -100% 0 13 Nov 2023 Common Stock 75,000 $2.84 Direct F9
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -670,000 -100% 0 13 Nov 2023 Common Stock 670,000 $2.99 Direct F10
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -163,000 -100% 0 13 Nov 2023 Common Stock 163,000 $4.32 Direct F11
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer -1,056,100 -100% 0 13 Nov 2023 Common Stock 1,056,100 $3.31 Direct F12
transaction SELB Employee Stock Option (right to buy) Disposed to Issuer $1,185,750 -1,275,000 -100% $0.9300 0 13 Nov 2023 Common Stock 1,275,000 $1.13 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This unvested restricted stock, which was granted on January 4, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for $113,300, representing $2.06 per share, the Cash-out Amount as applied in the Merger.
F2 This unvested restricted stock, which was granted on September 24, 2021, was canceled in the Merger, in exchange for $28,016, representing $2.06 per share, the Cash-out Amount as applied in the Merger.
F3 This unvested restricted stock, which was granted on January 3, 2022, was canceled in the Merger, in exchange for $349,633.50, representing $2.06 per share, the Cash-out Amount as applied in the Merger.
F4 This unvested restricted stock, which was granted on January 2, 2023, was canceled in the Merger, in exchange for $582,568, representing $2.06 per share, the Cash-out Amount as applied in the Merger.
F5 This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F6 This option, which provided for vesting as to 25% of the shares on February 25, 2020 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F7 This option, which provided for vesting as to 50% of the shares on October 7, 2020 and the remaining 50% of the shares on October 7, 2021, was canceled in the Merger, in exchange for a cash payment of $124,000, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.
F8 This option, which provided for vesting as to 25% of the shares on January 2, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F9 This option, which provided for vesting as to 25% of the shares on July 1, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F10 This option, which provided for vesting as to 25% of the shares on January 4, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F11 This option, which provided for vesting as to 25% of the shares on September 24, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F12 This option, which provided for vesting as to 25% of the shares on January 3, 2023 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.
F13 This option, which provided for vesting as to 25% of the shares on January 2, 2024 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger, in exchange for a cash payment of $1,185,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.